

01 APR 2005

PCT/EP 03/11024

IPC 7 C12N5/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CESANO A ET AL: "Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors"</p> <p>CANCER RESEARCH, vol. 56, no. 13, 1 July 1996 (1996-07-01), pages 3021-3029, XP001019009 ISSN: 0008-5472 cited in the application page 3022, "Large-scale expansion of TALL-104 cells for therapy"</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1-7, 11-16</p>

X Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A" document defining the general state of the art which is not considered to be of particular relevance
- *E" earlier document but published on or after the International filing date
- *I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O" document referring to an oral disclosure, use, exhibition or other means
- *P" document published prior to the International filing date but later than the priority date claimed

- *T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

1 March 2004

09/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer _____

Teyssier, B

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP 03/11024

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VISONNEAU S ET AL: "Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104."</p> <p>CLINICAL CANCER RESEARCH, vol. 3, no. 10, October 1997 (1997-10), pages 1789-1797, XP002236334 ISSN: 1078-0432 cited in the application page 1790, "Large-scale expansion of TALL-104 cells for therapy"</p>	1-7, 11-16
A	<p>TUYAERTS S ET AL: "Generation of large numbers of dendritic cells in a closed system using Cell Factories."</p> <p>JOURNAL OF IMMUNOLOGICAL METHODS, vol. 264, no. 1-2, 1 June 2002 (2002-06-01), pages 135-151, XP004362076 ISSN: 0022-1759</p>	
P,A	<p>BERGER T G ET AL: "Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories."</p> <p>JOURNAL OF IMMUNOLOGICAL METHODS, vol. 268, no. 2, 15 October 2002 (2002-10-15), pages 131-140, XP004379143 ISSN: 0022-1759</p>	